Rockefeller Capital Management’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Rockefeller Capital Management’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$101K	Buy	3,490 +1,168	+50%	+$33.9K	﹤0.01%	2865
2025 Q4	$60.8K	Buy	2,322 +251	+12%	+$6.46K	﹤0.01%	2981
2025 Q3	$48.9K	Buy	+2,071	New	+$45.8K	﹤0.01%	2929
2023 Q1	–	Sell	-2,504	Closed	-$63K	–	2882
2022 Q4	$63K	Sell	2,504 -80	-3%	-$2.15K	﹤0.01%	2265
2022 Q3	$68K	Buy	2,584 +2,078	+411%	+$64.1K	﹤0.01%	2198
2022 Q2	$14K	Sell	506 -16,086	-97%	-$480K	﹤0.01%	2941
2022 Q1	$571K	Buy	16,592 +430	+3%	+$15.2K	﹤0.01%	1272
2021 Q4	$708K	Buy	16,162 +3	+0%	+$142	﹤0.01%	1186
2021 Q3	$819K	Hold	16,159	–	–	﹤0.01%	1072
2021 Q2	$840K	Buy	16,159 +15,209	+1,601%	+$714K	﹤0.01%	999
2021 Q1	$43K	Buy	+950	New	+$46.4K	﹤0.01%	1949

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Rockefeller Capital Management's IDNA Position: Q1 2026 in Review

Rockefeller Capital Management increased its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 50% in Q1 2026, buying an estimated $33.9K and bringing the position to 3,490 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #2865.

Rockefeller Capital Management first reported a position in IDNA in Q1 2021 and has held it in 11 quarters since. The position peaked at $840K in Q2 2021. 60 funds tracked by Wall St. Rank hold IDNA as of Q1 2026.

Rockefeller Capital Management held 3,490 shares of iShares Genomics Immunology and Healthcare ETF worth $101K as of Q1 2026.
Rockefeller Capital Management bought 1,168 iShares Genomics Immunology and Healthcare ETF shares in Q1 2026, an estimated $33.9K.
iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #2865 holding.
Rockefeller Capital Management first reported a position in iShares Genomics Immunology and Healthcare ETF in Q1 2021 and has held it in 11 quarters since.
Rockefeller Capital Management's iShares Genomics Immunology and Healthcare ETF position peaked at $840K in Q2 2021.
60 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.